Malignant epithelioid hemangioendothelioma of the liver successfully treated with pegylated liposomal doxorubicin

Journal of Clinical Oncology

Volumn 29, Issue 25, 2011, Pages

  Grenader, Tal ^a   Vernea, Fiona ^a   Reinus, Constantin ^a   Gabizon, Alberto ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; CD34 ANTIGEN; DOXORUBICIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INFILTRATION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; HEMANGIOENDOTHELIOSARCOMA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER DYSFUNCTION; LIVER NODULE; LIVER SARCOMA; LUNG BIOPSY; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MULTIPLE PULMONARY NODULES; PRIORITY JOURNAL;

ADULT; DOXORUBICIN; HEMANGIOENDOTHELIOMA, EPITHELIOID; HUMANS; LIVER NEOPLASMS; MALE; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME;

EID: 80052708386     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.5891     Document Type: Article

References (13)

1. Mehrabi A, Kashfi A, Fonouni H, et al: Primary malignant hepatic epithelioid hemangioendothelioma: A comprehensive review of the literature with emphasis on the surgical therapy. Cancer 107:2108-2121, 2006 (Pubitemid 44665643)
2. Soloman R, Gabizon AA: Clinical pharmacology of liposomal anthracyclines: Focus on pegylated liposomal doxorubicin. Clin Lymphoma Myeloma 8:21-32, 2008
3. Judson I, Radford JA, Harris M, et al: Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: A study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 37:870-877, 2001 (Pubitemid 32323965)
4. Grenader T, Goldberg A, Hadas-Halperin I, et al: Long-term response to pegylated liposomal doxorubicin in patients with metastatic soft tissue sarcomas. Anticancer Drugs 20:15-20, 2009
5. Skubitz KM, Haddad PA: Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer 104:361-366, 2005 (Pubitemid 40993264)
6. Kelly H, O'Neil BH: Response of epithelioid haemangioendothelioma to liposomal doxorubicin. Lancet Oncol 6:813-815, 2005 (Pubitemid 41430723)
7. Northfelt DW, Martin FJ, Working P, et al: Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: Pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 36:55-63, 1996 (Pubitemid 26058811)
8. Huang SK, Lee KD, Hong K, et al: Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res 52:5135-5143, 1992
9. Cay O, Kruskal JB, Nasser I, et al: Liver metastases from colorectal cancer: Drug delivery with liposome-encapsulated doxorubicin. Radiology 205:95-101, 1997
10. Harrington KJ, Mohammadtaghi S, Uster PS, et al: Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 7:243-254, 2001 (Pubitemid 32183025)
11. Northfelt DW, Dezube BJ, Thommes JA, et al: Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol 15:653-659, 1997 (Pubitemid 27074235)
12. Safra T, Muggia F, Jeffers S, et al: Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 11:1029-1033, 2000
13. Grenader T, Goldberg A, Gabizon A: Monitoring long-term treatment with pegylated liposomal doxorubicin: How important is intensive cardiac follow-up? Anticancer Drugs 21:868-871, 2010